Velcade, Revlimid, and Thalomid are the leading brands, providing treatment for multiple myeloma in Asia Pacific. Analysts expect Revlimid, and Thalomid to maintain their dominance, owing to the absence of generic completion in the multiple myeloma therapeutics market in Asia Pacific, notes the market study. However, Velcade, the proteasome inhibitor, is likely to face severe challenge as its patent is going to expire in China by the end of 2015, in Japan by 2018, in Australia by 2020. The only consolation for this drug is its market in India, which is showing healthy growth. Over the 2014–2020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion.
Some of the new entrants in the Asia Pacific multiple myeloma therapeutics market are Daratumumab and Elotuzumab. Daratumumab has been trialed in combination with dexamethasone and Revlimid, and Elotuzumab has been trialed in combination with Revlimid only. Another drug, Kyprolis, is likely to be introduced in this region over the next few years.
Market experts anticipate these emerging treatments for multiple myeloma to offer alternatives in the refractory or relapsed disease setting, contributing significantly to the growth of this market.
Other prominent pipeline drugs for multiple myeloma are filanesib, Zolinza, and Plitidepsin, states the research report.
...